All In Biotech

Drug Trial Radar · NCT03315143

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,584 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

10,584

Actual

Start

Dec 19, 2017

Primary completion

Jul 8, 2020

Study completion Jul 8, 2020

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Oct 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure \[HHF\], and urgent visit for heart failure \[HF\] in participants with type 2 diabetes, cardiovascular risk factors, and moderate to severely impaired renal function.

Conditions

  • Heart Failure
  • Type 2 Diabetes Mellitus
  • Chronic Kidney Diseases

Interventions

  • SotagliflozinDrug

    Sotagliflozin was administered as a tablet(s), orally once daily.

  • PlaceboDrug

    Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)Time frame: Up to 30 months

Locations

754 sites in 45 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400017

    Birmingham, Alabama

  • Investigational Site Number 8400096

    Sheffield, Alabama

  • Investigational Site Number 8400004

    Mesa, Arizona

  • Investigational Site Number 8400059

    Mesa, Arizona

  • Investigational Site Number 8400021

    Peoria, Arizona

  • Investigational Site Number 8400014

    Surprise, Arizona

  • Investigational Site Number 8400071

    Little Rock, Arkansas

  • Investigational Site Number 8400039

    Beverly Hills, California

  • Investigational Site Number 8400042

    Concord, California

  • Investigational Site Number 8400089

    Fresno, California

  • Investigational Site Number 8400006

    Huntington Park, California

  • Investigational Site Number 8400036

    Long Beach, California

  • Investigational Site Number 8400073

    Los Angeles, California

  • Investigational Site Number 8400084

    Los Angeles, California

  • Investigational Site Number 8400035

    Los Gatos, California

  • Investigational Site Number 8400043

    Northridge, California

  • Investigational Site Number 8400025

    Sacramento, California

  • Investigational Site Number 8400018

    San Dimas, California

  • Investigational Site Number 8400070

    Temecula, California

  • Investigational Site Number 8400013

    Waterbury, Connecticut

  • Investigational Site Number 8400095

    Bradenton, Florida

  • Investigational Site Number 8400090

    Clearwater, Florida

  • Investigational Site Number 8400121

    Clearwater, Florida

  • Investigational Site Number 8400049

    Cooper City, Florida

  • Investigational Site Number 8400092

    Hialeah, Florida

  • Investigational Site Number 8400026

    Hollywood, Florida

  • Investigational Site Number 8400134

    Jacksonville, Florida

  • Investigational Site Number 8400055

    Jacksonville, Florida

  • Investigational Site Number 8400056

    Jacksonville, Florida

  • Investigational Site Number 8400031

    Jacksonville, Florida

  • Investigational Site Number 8400037

    Maitland, Florida

  • Investigational Site Number 8400078

    Miami, Florida

  • Investigational Site Number 8400117

    Miami, Florida

  • Investigational Site Number 8400119

    Miami, Florida

  • Investigational Site Number 8400118

    Miami, Florida

  • Investigational Site Number 8400105

    Miami, Florida

  • Investigational Site Number 8400120

    Miami, Florida

  • Investigational Site Number 8400088

    North Miami Beach, Florida

  • Investigational Site Number 8400106

    Opa-locka, Florida

  • Investigational Site Number 8400063

    Ormond Beach, Florida

Showing 40 of 754 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.